

**REMARKS**

In response to the Restriction/Election requirement mailed August 30, 2005, Applicants respectfully elect, with traverse, Group XVIII (claims 25-26, 28) drawn to a method for treating a solid tumor or suppressing neovascularization comprising administering a substance that inhibits binding between the ligand SDF-1 and the receptor CXCR4, classified in class 514, subclass 44.

Applicants respectfully traverse the restriction requirement, specifically, the restriction of claims 1-23 from Group XVIII. The invention of Group XVIII is performed with the therapeutic agents of claims 1-23. Accordingly, claims 1-23 and the claims of Group XVIII are related inventions and a search of the claims of Group XVIII would reveal the relevant art for claims 1-23. Thus, it would not be a burden to search and examine claims 1-23 with the claims of Group XVIII.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

Dated: February 28, 2006  
MORGAN, LEWIS & BOCKIUS LLP  
Customer No. 009629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel: 202-739-3000  
Fax: 202-739-3001



Sally P. Teng  
Reg. No. 45,397